Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma, Bronchiolo-Alveolar
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Lung Neoplasms
  • Quinazolines

abstract

  • Erlotinib is active in BAC and adenocarcinoma, mixed subtype, BAC. Testing for EGFR and KRAS mutations can predict RR and PFS after treatment with erlotinib in this histologically enriched subset of patients with non-small-cell lung cancer (NSCLC). These data suggest that histologic subtype and molecular characteristics should be reported in clinical trials in NSCLC using EGFR-directed therapy.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.13.0062

PubMed ID

  • 18349398

Additional Document Info

start page

  • 1472

end page

  • 8

volume

  • 26

number

  • 9